Lymphoblastoid cell line Daudi was used as the immunogen for this antibody.
Conjugation:
FITC
Alternative Names:
B-lymphocyte antigen CD20||B-lymphocyte surface antigen B1||Bp35||Leukocyte surface antigen Leu-16||Membrane-spanning 4-domains subfamily A member 1||CD_antigen: CD20
CD20 is clinically validated as an immunotherapy target for B-cell lymphomas and autoimmune diseases. CD20 consists of large, intracellular, amino- and carboxyterminal portions connected by 4 membrane-spanning domains. Its high expression on malignant B cells and its reported lack of shedding from the surface make CD20 an ideal target for antibody-mediated killing. Anti-CD20 antibodies are believed to mediate the therapeutic effect by activation of complement-dependent cytotoxicity (CDC) and largely by antibody-dependent cellular cytotoxicity exerted by recruitment of innate immune effector cells expressing the Fcgamma receptor IIIa.
